InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.66
(
-0.24%
)
US TECH 100
19,241.20
(
-0.12%
)
Dow Jones
39,009.90
(
-0.39%
)
Brent Oil
84.76
(
-0.77%
)
Bitcoin
60,656.76
(
-1.55%
)
Post# of 252422
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: poorgradstudent post# 87043

Monday, 12/07/2009 1:50:14 PM

Monday, December 07, 2009 1:50:14 PM

Post# of 252422
Agree that the approval path remains murky, I think that removing the peripheral neuropathy isn't enough, carfilzomib needs to show at least 25% ORR in Velcade refractory patients in order to get accelerated approval with this open label single arm phase IIb trial, so far it's 18%.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up